AstraZeneca PLC's Fiscal Year is From January To December.
The item "Ebit-Interest-Coverage" stands at 5.94 as of 09/30/2025.
As of the end of AstraZeneca PLC's third quarter, the item "Ebit Interest Coverage" stands at 5.94. This represents an increase of 24.24 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 0.4433 compared to the value the year prior.
The Serie's long term average value is 4.11. It's latest available value, on 09/30/2025, is 1.83 higher, compared to it's long term average value.
The Serie's change from it's minimum value, on 06/30/2022, to it's latest available value, on 09/30/2025, is +6.33 .
The Serie's change from it's maximum value, on 12/31/2024, to it's latest available value, on 09/30/2025, is -0.0577 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Ebit Interest Coverage | 905,699,262,464.00 |
![]() | Johnson & Johnson - Ebit Interest Coverage | 486,508,953,600.00 |
![]() | AbbVie Inc - Ebit Interest Coverage | 399,570,305,024.00 |
![]() | Roche Holding AG - Ebit Interest Coverage | 317,433,206,677.55 |
![]() | Novartis AG - Ebit Interest Coverage | 255,096,620,580.91 |